24 June 2024

We would like to congratulate our partners from the CanNanoVac consortium, the lab of Joke den Haan, with their latest publication on targeting Siglec1 with sdAb-decorated liposomes.

This work not only illustrates the application of sdAbs as targeting ligands on liposomes, it also showcases QVQs ability to generate lead molecules against heavily glycosylated targets.

In addition, the paper describes our anti-DC-SIGN product Q94c and anti-HIV gp120 product Q1c.

Please visit our product page for more sdAb reagents.